Validation of disease registration in pregnant women in the Medical Birth Registry of Norway
|
|
- Nickolas Marshall Logan
- 5 years ago
- Views:
Transcription
1 Acta Obstetricia et Gynecologica. 2009; 88: ORIGINAL ARTICLE Validation of disease registration in pregnant women in the Medical Birth Registry of Norway ANDERS ENGELAND 1,2, TONE BJØRGE 2,3, ANNE KJERSTI DALTVEIT 2,3, STEIN EMIL VOLLSET 2,3 & KARI FURU 1 1 Department of Pharmacoepidemiology, Division of Epidemiology, Norwegian Institute of Public Health, N-0403 Oslo, Norway, 2 Department of Public Health and Primary Health Care, University of Bergen, N-5018 Bergen, Norway, and 3 Medical Birth Registry of Norway, Division of Epidemiology, Norwegian Institute of Public Health, N-5018 Bergen, Norway Abstract Objective. To evaluate the reliability of maternal disease registration in the Medical Birth Registry of Norway (MBRN). Study design. Validation study. Setting. The two nationwide population-based registries, the Norwegian Prescription Database (NorPD) and the MBRN, were linked using a unique personal identification number. Population. Pregnant women (n108,489), pregnancies (lasting more than 22 weeks) starting at March 30, 2004 onwards and ending before January 1, 2007, registered in MBRN. Main outcome measures. Registrations of maternal diagnoses (diabetes, asthma, and epilepsy) in MBRN compared to their dispensal of prescribed medicines as an indication of disease. The sensitivity, specificity, and positive and negative predictive values of diabetes, epilepsy, and asthma in the MBRN were calculated using information from NorPD as the gold standard. Methods. Validation study comparing maternal diagnoses in MBRN with prescriptions of drugs and reimbursement codes registered in NorPD. Results. The sensitivity for the diagnosis of diabetes (any type) and diabetes type 1 in MBRN were estimated to be 72% (95% confidence interval: 6974) and 90% (8693%). For epilepsy and asthma, the sensitivity of MBRN was estimated to be 74% (6978) and 51% (4952), respectively. For asthma, the sensitivity increased to over 70% when it was restricted to individuals with more serious disease. Conclusions. The sensitivity of the registration of type 1 diabetes was 90%, while the sensitivity for any type of diabetes was lower and similar to the sensitivity of the registration of epilepsy. The registration of asthma overall was 51%, but considerably higher for more serious asthma. Except for diabetes type 1, the medical disease diagnoses in the MBRN should be dealt with carefully. Key words: Registration of maternal diseases, diabetes, epilepsy and asthma, registry Introduction The major objective of establishing the Medical Birth Registry of Norway (MBRN) in 1967 was to detect any increased rates for birth defects or other adverse pregnancy outcomes, and to establish a basis for epidemiological research. Some maternal diseases may increase the risk of congenital malformations as well as other perinatal health problems (1,2). Therefore, information on maternal diseases before and during pregnancy has been recorded in the registry. Particular attention has been paid to the course and outcome of pregnancy in women with diabetes (3,4), epilepsy (5,6), and hypertension (7). The validity of the information on maternal diseases in the MBRN is not well documented. However, the validity of diabetes mellitus diagnoses in the database has recently been explored (8). This was done using two sets of data; medical records (9,10) and the Norwegian Childhood Diabetes Registry (11). One of the conclusions from that evaluation was that the positive predictive value (PPV) for pre-gestational diabetes (80%) in 1998 was less than optimal, but acceptable. For gestational diabetes, the PPV was 90%. Furthermore, Hoff et al. (12) found a PPVof at least 88% for myasthenia gravis registered in MBRN during Skomsvoll et al. (13) found a Correspondence: Anders Engeland, Department of Pharmacoepidemiology, Division of Epidemiology, Norwegian Institute of Public Health, P.O. Box 4404 Nydalen, N-0403 Oslo, Norway. anders.engeland@isf.uib.no (Received 12 January 2009; accepted 18 June 2009) ISSN print/issn online # 2009 Informa UK Ltd. (Informa Healthcare, Taylor & Francis AS) DOI: /
2 1084 A. Engeland et al. sensitivity of 88% for maternal rheumatic disease in the MBRN before Most of these studies were based on data prior to 1998, when a new notification form was introduced in the MBRN. For some diseases (e.g. diabetes, epilepsy, asthma) specific medications are required, and are also used during pregnancy. The establishment of the Norwegian Prescription Database (NorPD) in 2004 made it possible to link data on maternal diseases before and during pregnancy from the MBRN with the use of medication (14). The aim of our study was to validate recorded disease diagnoses in MBRN using prescribed medicines and reimbursement codes in the NorPD as the standard. Material and methods Data sources NorPD (15) is a research database which captures all dispensed prescriptions in Norway from January 1, 2004, and covers the entire population of Norway (4.8 million). NorPD contains information on all prescribed drugs, reimbursed or not, dispensed at pharmacies to individual patients treated in ambulatory care. Data on use in institutionalized patients in nursing homes and hospitals are also collected, but these figures are only registered at an institutional and not at the individual level. Therefore, drugs dispensed to institutions are not included. For each prescription, the sex and age of the patient, demographic information, dispensal date, and detailed drug information are registered. The indication for prescribing is not recorded. However, the code of reimbursement is recorded (for all reimbursed drugs), and this may in some cases function as a proxy for diagnosis. In Norway, pharmaceutical treatment is reimbursed for a number of diseases or conditions (16). Reimbursement is given only when the patient has a chronic disease, for which long-term medication (more than three months) is necessary (16). Classification of drugs is based on the Anatomical Therapeutic Chemical (ATC) classification system as of 2007 (17). MBRN is a population-based registry containing information on all births in Norway since 1967 (more than 2.3 million) (18). MBRN is based on compulsory notification of every birth or late abortion from 12 completed weeks of gestation onwards, and includes identification of the parents by their national identification numbers, demographic information of the parents, maternal diagnoses before and during pregnancy, complications during pregnancy and delivery, length of pregnancy, as well as information on the infant, including birth defects and other perinatal problems (18). A standard antenatal form is completed at visits to a general practitioner, midwife, or obstetrician during pregnancy and is brought by the mother to the place of birth. The midwife enters additional data recorded at the time of birth. Followup data are added to the form until discharge of hospital births. Since 1998, data obtained in neonatal wards on congenital conditions for infants transferred to such units after birth have also been included. In our study, only pregnancies lasting more than 22 completed weeks were included. From late 1998, a new notification form for births was introduced. This form aimed to improve the registrations in MBRN. In this form there are precoded fields for disease in mothers prior to pregnancy, such as type 1 and 2 diabetes, asthma and epilepsy, and gestational diabetes. In addition, there are open text fields for maternal diagnoses before and during pregnancy. The use of drugs in pregnancy is also recorded. Textual information on maternal diseases is coded by the staff at the MBRN using International Classification of Diseases (ICD)-10 codes. Some women with polycystic ovary syndrome (PCOS) are prescribed metformin as treatment for infertility. PCOS is also associated with type 2 diabetes (19). We cannot, however, differentiate between diabetic and PCOS patients who are prescribed metformin. Hence, analyses were performed excluding prescriptions on metformin to women registered with PCOS in MBRN while studying diabetes overall and diabetes type 2. Study subjects Data in the MBRN were linked to NorPD using the unique 11-digit identification number, assigned to all individuals living in Norway after In our study, women with pregnancies registered in MBRN were included, beginning at March 30, 2004 or later and ending before January 1, Only the first pregnancy during the study period was included for each woman. Prescription data from NorPD from January 2004 until December 31, 2006 were used. March 30, 2004 was defined as the starting date of pregnancies to ensure that information on all prescriptions dispensed from three months before conception until the end of pregnancy was included. Methodology Length of pregnancy was usually determined by routine ultrasound around week 18 (97%) and the date of conception estimated. Each pregnancy was
3 Registration of maternal diseases 1085 divided into trimesters (week 012, week 1326, and week 27 onwards). Prescriptions during the three last months before conception and during pregnancy were included from NorPD. Prescriptions of specific drugs, combined with reimbursement codes, were used as proxies of disease:. Dispensed drugs used to treat diabetes (ATC code A10) were used as proxy for any type of diabetes. Dispensed insulin (A10A) could more specifically also be used as an indicator of type 1 or gestational diabetes. To distinguish between patients with type 1 and gestational diabetes, insulin prescriptions dispensed during the three months before conception were used.. Dispensed selective beta-2-adrenoreceptor agonists as inhalants (ATC code R03AC), fixed dose combination of inhaled beta-2-adrenoreceptor agonists and long-acting glucocorticoids (R03AK), inhalants of glucocorticoids and anticholinergics (R03B), or other systemic drugs for obstructive airway diseases (R03D) with specific reimbursement codes were used as a proxy for asthma. According to guidelines, medical treatment of asthma should follow a stepwise approach until control of symptoms is achieved using the lowest possible dose (20). Each step could be indicated by the type of drugs prescribed: (1) Inhaled selective beta-2-adrenoreceptor agonists (R03AC). (2) Inhaled glucocorticoids (R03BA). (3) Both R03AC and R03BA or adrenergics, and other drugs for obstructive airway diseases (R03AK). (4) Other systemic drugs for obstructive airway diseases (R03D).. Dispensed antiepileptics (ATC code N03A) with a specific reimbursement code were used as a proxy for epilepsy. Using registration in NorPD as the gold standard, we calculated the sensitivity, specificity, and positive and negative predictive values:. the sensitivity of diagnoses in MBRN was calculated as the proportion of those diagnosed in NorPD who were diagnosed in MBRN;. the specificity was calculated as the proportion of those not diagnosed in NorPD who were not diagnosed in MBRN either;. the PPV was calculated as the proportion diagnosed in MBRN who were also diagnosed in NorPD; and. the negative predictive value (NPV) was calculated as the proportion not diagnosed in MBRN who were not diagnosed in NorPD either. For sensitivity, specificity, PPV, and NPV, 95% confidence intervals (95% CI) were calculated using continuity corrected score intervals (21). Results A total of 108,489 pregnancies were included in our study, 376 (0.3%) of the mothers were registered with PCOS. According to data from MBRN, a total of 1,929 (1.8%) mothers were registered with diabetes, 855 (0.8%) with epilepsy, and 4,549 (4.2%) with asthma (Table I). For all diagnoses studied, the estimated specificity was close to 100%. Calculations Table I. Characteristics of the study population. Data from pregnancies in (n108,489), Medical Birth Registry of Norway (MBRN). Total number of women Percentage (%) Age (years) B20 2, , , , Birth year B , , , Length of pregnancy (completed weeks) , , , , Diabetes in MBRN Yes 1, Epilepsy in MBRN Yes Asthma in MBRN Yes 4, Pregnancy outcome Abortion Stillbirth Livebirth 108,
4 1086 A. Engeland et al. using six months instead of three months prior to conception, gave similar results for diabetes, epilepsy, and asthma. Diabetes Of 1,929 women registered with diabetes in MBRN before or during pregnancy, 926 (48%) were dispensed with at least one drug used in the treatment of diabetes. In addition, 363 women who were not registered with diabetes in the MBRN were dispensed drugs used to treat diabetes. Among the women who received such drugs, 926 (72%) were registered in the MBRN as having diabetes, i.e. a sensitivity of 72% (Table II). The PPV of diabetes registered in MBRN was 48%. Of the 1,289 women dispensed drugs used to treat diabetes, most received fast (56%) and intermediate-acting (50%) insulin and analogs for injection (ATC codes A10AB and A10AC, Table III). While excluding metformin-prescriptions in women with PCOS, 899 of 1,198 women who were dispensed drugs used to treat diabetes, were registered with diabetes in MBRN, i.e. a sensitivity of 75%. A total of 1,060 women were registered with gestational diabetes in MBRN. Among these, 32 (3%) received drugs used to treat diabetes during the three months prior to conception, seven of these women had PCOS and received metformin. Among women registered with gestational diabetes not receiving drugs prior to conception, 25% received drugs during pregnancy. According to MBRN, 520 women had type 1 diabetes. Of these, 307 (59%) received drugs used to treat diabetes during the three months before conception. Excluding metformin-prescriptions in women with PCOS, one of these women was removed. Of the women registered with type 1 diabetes, a total of 289 (56%) were dispensed insulins during the three months before conception. Of those not registered in MBRN as having type 1 diabetes, 33 (0.03%) were dispensed insulin. A total of 461 (89%) women registered with type 1 diabetes were dispensed insulin during the three months before conception and during pregnancy. In addition, 409 women not registered as having type 1 diabetes also received insulin. Of these, 281 were registered as having gestational diabetes. Of 221 women registered with type 2 diabetes in MBRN, 99 (45%) received drugs used to treat diabetes. While excluding metformin-prescriptions in women with PCOS, 97 of these women were dispensed drugs used to treat diabetes. Epilepsy A total of 314 (37%) women registered with epilepsy in MBRN received drugs for epilepsy. The sensitivity for epilepsy of the registry was estimated to be 74%. In women who were not registered in MBRN as having epilepsy, 112 used epilepsy drugs and 74 of these were dispensed epilepsy drugs during pregnancy. Asthma Of women registered with asthma in MBRN, 2,098 (46%) were dispensed drugs for asthma. In women not registered in the MBRN as having asthma, 2,043 (2%) used asthma drugs. Of all women who were dispensed drugs for asthma, about half (51%) were registered with a diagnosis of asthma in MBRN. The sensitivity of registration of asthma in the MBRN increased according to the seriousness of asthma Table II. Registered diseases in the Medical Birth Registry of Norway (MBRN) in women (n108,489) before and during pregnancy vs. diseases diagnosed using prescriptions and reimbursement codes registered in the Norwegian Prescription Database (NorPD). Disease in both registries (A) Disease only in MBRN (B) Disease only in NorPD (C) Sensitivity a (95% CI) Positive predictive value (PPV) b (95% CI) Specificity c (95% CI) Diabetes (any type) 926 1, (6974) 48 (4650) 99 (9999) Type 1 diabetes d (8693) 56 (5160) 100 (100100) Epilepsy (6978) 37 (3440) 100 (99100) Asthma e 2,098 2,451 2, (4952) 46 (4548) 98 (9898) Step I 636 3, (3842) 14 (1315) 96 (9696) Step IIIII 1,255 3, (5660) 28 (2629) 97 (9797) Step IV 128 4, (6679) 3 (23) 96 (9696) a SensitivityA/(AC). b PPVA/(AB). c SpecificityD/(BD). d Diagnosis in NorPD based on dispensed insulins (ATC: A10A) during the three months prior to conception. e Based on guidelines for medical treatment of asthma, asthmatic women were divided into groups according to assumed seriousness of their asthma (20).
5 Table III. Dispensed drugs for diabetes, epilepsy, and asthma from three months prior to conception until birth for pregnant women (n108,489). Data from the Norwegian Prescription Database (NorPD). Number of women with]1 prescription Disease Dispensed drugs (ATC code) Total Three months before conception First trimester Second trimester Third trimester Diabetes Insulins and analogs for injection, fast-acting (A10AB) Insulins and analogs for injection, intermediate-acting (A10AC) Insulins and analogs for injection, intermediate-acting combined with fast-acting (A10AD) Insulins and analogs for injection, fast-acting (A10AE) Biguanides (A10BA) Sulfonamides, urea derivatives (A10BB) Thiazolidineones (A10BG) Epilepsy Phenobarbital (N03AA02) Phenotyin (N03AB02) Phensuximide (N03AD01) Clonazepam (N03AE01) Carbamazepine (N03AF01) Oxcarbazepine (N03AF02) Valproic acid (N03AG01) Lamotrigine (N03AX09) Topiramate (N03AX11) Gabapentin (N03AX12) Levetiracetam (N03AX14) (N03AX16) Asthma Selective beta-2 adrenoreceptor antagonists (R03AC) 3,150 1,299 1,181 1,274 1,212 Adrenergics and other drugs for obstructive airway 1, diseases (R03AK) Glucocortisoids (R03BA) Anticholinergics (R03BB) Antiallergic agents, excl. corticosteroids (R03BC) Xanthines (R03DA) Leukotriene receptor antagonists (R03DC) Registration of maternal diseases 1087
6 1088 A. Engeland et al. (see Methods ): Step I, sensitivity 40%; Step IIIII, sensitivity 58%; Step IV, sensitivity 73%. Discussion In this population-based study, we validated the registration of diseases in women in the MBRN using prescribed medicines and reimbursement codes registered in NorPD as the gold standard. We observed a sensitivity of the registration of type 1 diabetes of 90%, while the sensitivity for any type of diabetes was lower and similar to the sensitivity of the registration of epilepsy (72 and 74%). The sensitivity of the registration of asthma was about 51%, but considerably higher for those with more serious disease. A major strength of our study was the use of two nationwide registries and the unique 11-digit identification number, which ensured valid data linkage between the two registries. Another advantage was that the NorPD includes prescriptions from all practicing physicians prescribing to patients living outside institutions in Norway, both general practitioners and specialists. In addition, NorPD has not previously been used in studies assessing the validity of maternal disease diagnoses in MBRN. Diseases included in our study were those which were easily identifiable through the prescription of drugs, i.e. diseases where the use of specific medicines, combined with reimbursement codes, implies the presence of the disease. However, the absence of prescriptions does not necessarily imply absence of the disease. Moreover, women who receive medication as inpatients in hospitals were not included in NorPD. For this reason, we were only able to give estimates of the minimum PPV in MBRN on the assumption that those who were dispensed the disease-specific drugs (for epilepsy and asthma also with the relevant reimbursement codes) had the disease. If we also assumed that among those not being dispensed drugs, the proportion of true diagnoses registered in MBRN was equal to or less than among those dispensed drugs, the maximum sensitivity in MBRN could be calculated. Since most pregnant women do not have any of the diseases we are studying, the specificity for all these diseases will be close to 100%. In addition, women with the diseases do not necessarily need medication during the period studied here. Data on drugs prescribed, rather than dispensed, can lead to the misclassification of drug exposure because of primary non-compliance (22). Our data were based on dispensed rather than prescribed drugs, and this may increase the usefulness of the data. Assuming that those who received drugs used to treat diabetes were correctly diagnosed with diabetes, the sensitivity of diabetes in MBRN was at most 72%. Not all patients with diabetes use these drugs. We do not know whether women not receiving drugs for diabetes in connection with pregnancy were diabetics or not. However, in the USA, 16% of adults with diagnosed diabetes (type 1 or type 2), do not take insulin or oral medication (23). If we base estimates on dispensed drugs in the three months before conception, at least 6% of the mothers registered with gestational diabetes in the MBRN had diabetes before pregnancy. Using dispensed insulin as a measure, the sensitivity of type 1 diabetes in MBRN was at most 90%. This is in agreement with a recent study by Stene et al. (8), comparing registrations in the MBRN with registrations in the Norwegian Childhood Diabetes Registry for births in In that study, a sensitivity of 88% was observed for registration of type 1 diabetes in MBRN. For this disease most patients will need prescriptions of insulin regularly. Assuming that those receiving drugs for epilepsy had a correct diagnosis (epilepsy), the sensitivity was at most 74%. Among those not diagnosed in MBRN, a large proportion was dispensed anti-epileptics during pregnancy. This diagnosis has been used in a recent study looking at the adult intelligence in offspring of mothers with epilepsy (6). In that study, Øyen et al. found a prevalence of maternal epilepsy of 4.1/1,000, using births from 1967 to In our study, the prevalence of maternal epilepsy registered in MBRN was 7.9/1,000. Assuming that individuals who received drugs for asthma actually had asthma, the sensitivity of the asthma diagnosis in MBRN was, at most, 51%. However, the sensitivity of registration of asthma in MBRN seemed to increase according to the seriousness of the disease. Due to the low sensitivity, analyses including this diagnosis should be interpreted with caution. In conclusion, the registration of diabetes (any type) and epilepsy in MBRN was estimated to have sensitivity of 72 and 74%, respectively. The sensitivity of the registration of type 1 diabetes was higher (90%), while the sensitivity of the registration of asthma, in general, was only 51%. However, a higher sensitivity of asthma was achieved when the analysis was restricted to individuals presumed to have more serious disease. Except for diabetes type 1, the
7 Registration of maternal diseases 1089 diagnoses in MBRN explored in this study should be dealt with very carefully. Declaration of interest: The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper. References 1. Holmes LB, Harvey EA, Coull BA, Huntington KB, Khoshbin S, Hayes AM, et al. The teratogenicity zof anticonvulsant drugs. N Engl J Med. 2001;/344:/ Macintosh MC, Fleming KM, Bailey JA, Doyle P, Modder J, Acolet D, et al. Perinatal mortality and congenital anomalies in babies of women with type 1 or type 2 diabetes in England, Wales, and Northern Ireland: population based study. BMJ. 2006;333: Egeland GM, Skjærven R, Irgens LM. Birth characteristics of women who develop gestational diabetes: population based study. BMJ. 2000;/321:/ Egeland GM, Skjærven R, Irgens LM. The reproductive health of daughters of pregestational diabetic women: Medical Birth Registry of Norway. Paediatr Perinat Epidemiol. 2002;/ 16:/ King PB, Lie RT, Irgens LM. Spina bifida and cleft lip among newborns of Norwegian women with epilepsy: changes related to the use of anticonvulsants. Am J Public Health. 1996;/86:/ Øyen N, Vollset SE, Eide MG, Bjerkedal T, Skjærven R. Maternal epilepsy and offsprings adult intelligence: a population-based study from Norway. Epilepsia. 2007;/48:/ Rasmussen S, Irgens LM. History of fetal growth restriction is more strongly associated with severe rather than milder pregnancy-induced hypertension. Hypertension. 2008;/51:/ Stene LC, Eidem I, Vangen S, Joner G, Irgens LM, Moe N. The validity of the diabetes mellitus diagnosis in the Medical Birth Registry of Norway. Nor J Epidemiol. 2007;/17:/ Hawthorne G, Irgens LM, Lie RT. Outcome of pregnancy in diabetic women in northeast England and in Norway, BMJ. 2000;/321:/ Hawthorne G, Irgens LM, Lie RT, Moe N, Jervell J. Retraction of paper on maternal diabetes. BMJ. 2003; 327: Aamodt G, Stene LC, Njølstad PR, Søvik O, Joner G. Spatiotemporal trends and age-period-cohort modeling of the incidence of type 1 diabetes among children aged B15 years in Norway and Diabetes Care. 2007;/30:/ Hoff JM, Daltveit AK, Gilhus NE. Myasthenia gravis in pregnancy and birth: identifying risk factors, optimising care. Eur J Neurol. 2007;/14:/ Skomsvoll JF, Østensen M, Baste V, Irgens LM. Validity of a rheumatic disease diagnosis in the Medical Birth Registry of Norway. Acta Obstet Gynecol Scand. 2002;/81:/ Engeland A, Bramness JG, Daltveit AK, Rønning M, Skurtveit S, Furu K. Prescription drug use among fathers and mothers before and during pregnancy. A populationbased cohort study of 106,000 pregnancies in Norway Br J Clin Pharmacol. 2008;/69:/ Furu K. Establishment of the nationwide Norwegian Prescription Database (NorPD) new opportunities for research in pharmacoepidemiology in Norway. Nor J Epidemiol. 2008;/ 18:/ Hågå A, Sverre J. Pricing and reimbursement of pharmaceuticals in Norway. Eur J Health Econ. 2002;/3:/ WHO Collaborating Centre for Drug Statistics Methodology. ATC classification index with DDDs Oslo, Norway: WHO Collaborating Centre for Drug Statistics Methodology; Irgens LM. The Medical Birth Registry of Norway. Epidemiological research and surveillance throughout 30 years. Acta Obstet Gynecol Scand. 2000;/79:/ Glueck CJ, Goldenberg N, Sieve L, Wang P. An observational study of reduction of insulin resistance and prevention of development of type 2 diabetes mellitus in women with polycystic ovary syndrome treated with metformin and diet. Metabolism. 2008;/57:/ Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention Available online at: (Assessed April 15, 2009). 21. Vollset SE. Confidence intervals for a binomial proportion. Stat Med. 1993;/12:/ Beardon PH, McGilchrist MM, McKendrick AD, McDevitt DG, MacDonald TM. Primary non-compliance with prescribed medication in primary care. BMJ. 1993;/307:/ Centers for Disease Control and Prevention.National diabetes fact sheet: general information and national estimates on diabetes in the United States, Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention; 2008.
Self-reported data on medicine use in the Norwegian Mother and Child cohort study compared to data from the Norwegian Prescription Database
Norsk Epidemiologi 2014; 24 (1-2): 209-216 209 Self-reported data on medicine use in the Norwegian Mother and Child cohort study compared to data from the Norwegian Prescription Database Svetlana Skurtveit
More informationSupplementary Online Content
Supplementary Online Content Mølgaard-Nielsen D, Hviid A. Newer-generation antiepileptic drugs and the risk of major birth defects. JAMA. 2011;305(19):1996-2002. emethods. Birth defects and potential confounders
More informationDrug prescriptions (Pharm) Exposure (36/48 months)
ANNEX SECTION PART A - Study design: Figure 1 overview of the study design Drug prescriptions (Pharm) 2006-2010 Exposure (36/48 months) flexible time windows (e.g. 90 days) time index date (hospital discharge)
More information11b). Does the use of folic acid preconceptually decrease the risk of foetal malformations in women with epilepsy?
updated 2012 Management of epilepsy in women of child bearing age Q11: 11a). In women with epilepsy, should antiepileptic therapy be prescribed as monotherapy or polytherapy to decrease the risk of fetal
More informationPerinatal and infant mortality in term and preterm births among women with type 1 diabetes
Diabetologia (211) 54:2771 2778 DOI 1.17/s125-11-2281-7 ARTICLE Perinatal and infant mortality in term and preterm births among women with type 1 diabetes I. Eidem & S. Vangen & K. F. Hanssen & S. E. Vollset
More informationRepeated dispensing of codeine is associated with high consumption of benzodiazepines
Norsk Epidemiologi 2008; 18 (2): 185-190 185 Repeated dispensing of codeine is associated with high consumption of benzodiazepines Liliana C. Bachs 1, Jørgen G. Bramness 2, Anders Engeland 2,3 and Svetlana
More informationMaternal smoking and birthweight: effect modification of period, maternal age and paternal smoking
Acta Obstet Gynecol Scand 2000; 79: 485 489 Copyright C Acta Obstet Gynecol Scand 2000 Printed in Denmark All rights reserved Acta Obstetricia et Gynecologica Scandinavica ISSN 0001-6349 ORIGINAL ARTICLE
More informationAsthma in Pregnancy. Michael Schatz, MD, MS Department of Allergy Kaiser Permanente Medical Center San Diego, CA. Introduction
Asthma in Pregnancy Michael Schatz, MD, MS Department of Allergy Kaiser Permanente Medical Center San Diego, CA Introduction Asthma is the most common potentially serious medical problem to complicate
More informationInformation on the risks of Valproate (Epilim) use in girls (of any age), women of childbearing potential and pregnant women.
CONTAINS NEW INFORMATION GUIDE FOR HEALTHCARE PROFESSIONALS Information on the risks of Valproate (Epilim) use in girls (of any age), women of childbearing potential and pregnant women. Read this booklet
More informationBirth Rate among Patients with Epilepsy: A Nationwide Population-based Cohort Study in Finland
American Journal of Epidemiology Copyright 2004 by the Johns Hopkins Bloomberg School of Public Health All rights reserved Vol. 159, No. 11 Printed in U.S.A. DOI: 10.1093/aje/kwh140 Birth Rate among Patients
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Svanström H, Pasternak B, Hviid A. Use of azithromycin and
More informationTeratogenic and other considerations in the selection of antiepileptic drugs in girls and women
3 rd Congress of the European Academy of Neurology Amsterdam, The Netherlands, June 24 27, 2017 Teaching Course 7 Treatment of women with epilepsy - Level 1-2 Teratogenic and other considerations in the
More informationRisk of congenital anomalies after exposure to asthma medication in the first trimester of pregnancy a cohort linkage study
DOI: 10.1111/1471-0528.14026 www.bjog.org Risk of congenital anomalies after exposure to asthma medication in the first trimester of pregnancy a cohort linkage study E Garne, a A Vinkel Hansen, a J Morris,
More informationPregnancy, delivery, and outcome for the child in maternal epilepsy
FULL-LENGTH ORIGINAL RESEARCH Pregnancy, delivery, and outcome for the child in maternal epilepsy *zgyri Veiby, yxanne K. Daltveit, *zbernt A. Engelsen, and *znils E. Gilhus *Department of Clinical Medicine,
More informationAnnex III. Amendments to relevant sections of the summary of product characteristics and package leaflets
Annex III Amendments to relevant sections of the summary of product characteristics and package leaflets Note: These amendments to the relevant sections of the Summary of Product Characteristics and package
More informationThe Safety of Asthma and Allergy Medications in Pregnancy: New Horizons
The Safety of Asthma and Allergy Medications in Pregnancy: New Horizons Jennifer Namazy, MD Division of Allergy Scripps Clinic, San Diego Michael Schatz, MD, MS Department of Allergy Kaiser Permanente,
More informationNIH Public Access Author Manuscript N Engl J Med. Author manuscript; available in PMC 2013 March 18.
NIH Public Access Author Manuscript Published in final edited form as: N Engl J Med. 2013 January 24; 368(4): 333 340. doi:10.1056/nejmoa1207210. Risk of fetal death after pandemic influenza infection
More informationار ناج هکنآ مان هب تخومآ
فکرت را جان آنکه به نام آموخت صرع در حاملگی بیش از 90 درصد مادران مصروع می توانند فرزندان طبیعی داشته باشند Are antiepileptic drugs necessary? What effect do antiepileptic drugs have on the fetus? What
More informationTeratogenic Effects of Antiepileptic Medications
Teratogenic Effects of Antiepileptic Medications Torbj rn Tomson, MD, PhD a,b, *, Dina Battino, MD c KEYWORDS Epilepsy Pregnancy Antiepileptic drugs Teratogenicity Birth defects It has been estimated that
More informationDisclosures. Objectives 2/16/2015. Women with Epilepsy: Seizures in Pregnancy and Maternal/Fetal Outcomes
Women with Epilepsy: Seizures in Pregnancy and Maternal/Fetal Outcomes 40 th Annual Progress in OBGYN February 19, 2015 Jennifer L. DeWolfe, DO Associate Professor UAB Epilepsy Center Director, BVAMC Sleep
More informationXournals. The Use Antiepileptic Drug (AED) during Pregnancy. Surya Kiran Sharma 1. Abstract: Authors:
ISSN UA Volume 01 Issue 01 June-2018 The Use Antiepileptic Drug (AED) during Pregnancy Surya Kiran Sharma 1 Available online at: www.xournals.com Received 13 th December 2017 Revised 15 th February 2018
More informationResearch Article Use of Antiasthmatic Drugs during Pregnancy after the First Trimester and Maternal and Neonatal Outcomes
Respiratory Medicine, Article ID 209583, 7 pages http://dx.doi.org/10.1155/2014/209583 Research Article Use of Antiasthmatic Drugs during Pregnancy after the First Trimester and Maternal and Neonatal Outcomes
More informationManagement of Pregestational and Gestational Diabetes Mellitus
Background and Prevalence Management of Pregestational and Gestational Diabetes Mellitus Pregestational Diabetes - 8 million women in the US are affected, complicating 1% of all pregnancies. Type II is
More informationThe Use of Central Nervous System Active Drugs During Pregnancy
Pharmaceuticals 2013, 6, 1221-1286; doi:10.3390/ph6101221 OPEN ACCESS pharmaceuticals ISSN 1424-8247 www.mdpi.com/journal/pharmaceuticals Review The Use of Central Nervous System Active Drugs During Pregnancy
More informationPregnancy and Epilepsy
Pregnancy and Epilepsy Nowhere is the problem more evident or more complicated than in pregnancy. In the United States, epilepsy affects nearly one million women of childbearing potential. Alarm bells
More informationGSK Medicine: Study Number: Title: Rationale: Study Period: Objectives: Indication: Study Investigators/Centers: Data Source:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationPregnancy, birth and postnatal information for women who have epilepsy
Pregnancy, birth and postnatal information for women who have epilepsy This leaflet is for pregnant women with epilepsy. It explains what complications may occur, how your pregnancy will be monitored because
More informationValidity of data sources in pharmacoepidemiology
Validity of data sources in pharmacoepidemiology Jesper Hallas MD DrMedSc Dept of clinical pharmacology University of Southern Denmark, Odense jhallas@health.sdu.dk Disposition 1. Defining validity 2.
More information2018 Standard of Medical Care Diabetes and Pregnancy
2018 Standard of Medical Care Diabetes and Pregnancy 2018 Standard of Medical Care Diabetes and Pregnancy Marjorie Cypress does not have any relevant financial relationships with any commercial interests
More informationParental antibiotics and childhood asthma : a population-based study. Örtqvist, A.K.; Lundholma, C.; Fang, F.; Fall, T.; Almqvist, C.
This is an author produced version of a paper accepted by Journal of Allergy and Clinical Immunology. This paper has been peer-reviewed but does not include the final publisher proof-corrections or journal
More informationComplete the Qsymia Healthcare Provider Training Program in 2 easy steps:
Overview FDA has required a Risk Evaluation and Mitigation Strategy (REMS) for Qsymia so that healthcare providers can be informed about the increased risk of teratogenicity associated with Qsymia therapy.
More informationThe validity of the diagnosis of inflammatory arthritis in a large population-based primary care database
Nielen et al. BMC Family Practice 2013, 14:79 RESEARCH ARTICLE Open Access The validity of the diagnosis of inflammatory arthritis in a large population-based primary care database Markus MJ Nielen 1*,
More informationOverview Purpose Complete the Qsymia Pharmacy Certification in 3 easy steps:
Overview The Food and Drug Administration (FDA) has required a Risk Evaluation and Mitigation Strategy (REMS) for Qsymia to ensure the benefits of Qsymia outweigh the increased risk of teratogenicity.
More informationOverview. Purpose. Qsymia (phentermine and topiramate extended-release) capsules CIV Pharmacy Training Program
Qsymia (phentermine and topiramate extended-release) capsules CIV Pharmacy Training Program Overview The Food and Drug Administration (FDA) has required a Risk Evaluation and Mitigation Strategy (REMS)
More informationCOMPLICATIONS OF PRE-GESTATIONAL AND GESTATIONAL DIABETES IN SAUDI WOMEN: ANALYSIS FROM RIYADH MOTHER AND BABY COHORT STUDY (RAHMA)
COMPLICATIONS OF PRE-GESTATIONAL AND GESTATIONAL DIABETES IN SAUDI WOMEN: ANALYSIS FROM RIYADH MOTHER AND BABY COHORT STUDY (RAHMA) Prof. Hayfaa Wahabi, King Saud University, Riyadh Saudi Arabia Hayfaa
More informationAnatomical Therapeutic Chemical Classification (ATC) & And Defined Daily Dose (DDD) Principles for classifying and quantifying drug use
Anatomical Therapeutic Chemical Classification (ATC) & And Defined Daily Dose (DDD) Principles for classifying and quantifying drug use Margaret Oluka Course outline/objectives 1. Introduction: drug classification
More informationAnnex I. Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation(s)
Annex I Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation(s) 1 Scientific conclusions Taking into account the PRAC Assessment Report on the PSUR(s) for topiramate,
More informationBenefits and risks of taking antiepileptic medicine for females Information for healthcare professionals
Benefits and risks of taking antiepileptic medicine for females Information for healthcare professionals 2 Benefits and risks of taking antiepileptic medicine for females 3 This booklet provides information
More informationA study of neonatal and maternal outcomes of asthma during pregnancy
International Journal of Research in Medical Sciences Meena BL et al. Int J Res Med Sci. 2013 Feb;1(1):23-27 www.msjonline.org pissn 2320-6071 eissn 2320-6012 Research Article DOI: 10.5455/2320-6012.ijrms20130206
More informationGuidance on prescribing valproate for bipolar disorder in women of child-bearing potential
Guidance on prescribing valproate for bipolar disorder in women of child-bearing potential Background Valproate is prescribed for mood stabilisation in bipolar disorder; however it is wellestablished as
More informationVishwanath Pattan Endocrinology Wyoming Medical Center
Vishwanath Pattan Endocrinology Wyoming Medical Center Disclosure Holdings in Tandem Non for this Training Introduction In the United States, 5 to 6 percent of pregnancies almost 250,000 women are affected
More informationRisk of Fetal Death after Pandemic Influenza Virus Infection or Vaccination
T h e n e w e ngl a nd j o u r na l o f m e dic i n e original article Risk of Fetal Death after Pandemic Influenza Virus Infection or Vaccination Siri E. Håberg, M.D., Ph.D., Lill Trogstad, M.D., Ph.D.,
More informationLinkage of birth data in Europe. Marie Delnord EPOPé INSERM
Linkage of birth data in Europe Marie Delnord EPOPé INSERM Perinatal health data sources Perinatal care is multidisciplinary : Involves midwives, obstetricians, paediatricians, and other sub-specialists.
More informationAir pollution and public health
Air pollution and public health A. Van Nieuwenhuyse CORDEX meeting, September 25, 2017 Rue Juliette Wytsmanstraat 14 1050 Brussels Belgium T +32 2 642 51 11 F +32 2 642 50 01 email: info@wiv-isp.be www.wiv-isp.be
More informationOutline. Definitions. ATC Anatomical Therapeutic Chemical classification
The Anatomical Therapeutic Chemical Classification and the Defined Daily Dose: Classifying and Quantifying Drug Use Hanne Strøm Department of Pharmacoepidemiology ICPE, Chicago August 2011 : Preconference
More informationTERATOGENIC DETERMINANTS OF FIRST- TRIMESTER EXPOSURE TO ANTIEPILEPTIC MEDICATIONS
TERATOGENIC DETERMINANTS OF FIRST- TRIMESTER EXPOSURE TO ANTIEPILEPTIC MEDICATIONS Koby Brosh 1, Ilan Matok 7, Eyal Sheiner 1,3,5, Gideon Koren,7,8,9, Arnon Wiznitzer 1,3, 5,6, Rafael Gorodischer 1,4,5,6,9,
More informationPharmacologic Considerations in the Pregnant Patient (For the PCP)
Pharmacologic Considerations in the Pregnant Patient (For the PCP) Aspirin Use in Pregnancies At Risk Contemporary Treatment of the A2 Diabetic Statin Exposure in Early Pregnancy Continuation of SSRI Rx
More informationAspects of statin prescribing in Norwegian counties with high, average and low statin. Department of Pharmacy, University of Tromsø, Tromsø, Norway
Title page Aspects of statin prescribing in Norwegian counties with high, average and low statin consumption - an individualised prescription database study Ingeborg Hartz, 1 Solveig Sakshaug, 2 Kari Furu
More informationInternational Registries: The Government-Driven Model
International Registries: The Government-Driven Model Pål Surén Norwegian Institute of Public Health Presentation outline Overview of Norwegian health registries The Norwegian Mother and Child Cohort Study
More informationPregnancies complicated by diabetes. Marina Mickleson Nurse Practitioner Midwife CDE
Pregnancies complicated by diabetes Marina Mickleson Nurse Practitioner Midwife CDE Two types Pre gestational Gestational diabetes Both types are on the increase Pre conception work up is imperative for
More informationBirth characteristics and asthma symptoms in young adults: results from a population-based cohort study in Norway
Eur Respir J 998; 2: 6 7 DOI:./996.98.266 Printed in UK - all rights reserved Copyright ERS Journals Ltd 998 European Respiratory Journal ISSN 9-96 Birth characteristics and asthma symptoms in young adults:
More information2011 MNA Midwest Summer Conference
2011 MNA Midwest Summer Conference Women and Epilepsy Marianna V. Spanaki, M.D., Ph.D., M.B.A. SENIOR STAFF NEUROLOGIST DIRECTOR EPILEPSY MONITORING UNIT HENRY FORD COMPREHENSIVE EPILEPSY PROGRAM HENRY
More informationMedications for Epilepsy What I Need to Know
Medications for Epilepsy What I Need to Know Safiya Ladak, BSc.Phm. Toronto Western Hospital, UHN Clinical Pharmacist, Neurology and Neurosurgery June 4, 2016 Learning Objectives Treatment options for
More informationDiabetes: The Effects of Maternal Diabetes on Fetal Development and Outcomes Sherrie McElvy, MD May 18, 2016
Diabetes: The Effects of Maternal Diabetes on Fetal Development and Outcomes Sherrie McElvy, MD May 18, 2016 Medical Director Sweet Success Sutter Medical Center Sacramento Perinatal Associates of Sacramento
More informationOUTCOMES OF INFANTS EXPOSED TO MULTIPLE ANTIDEPRESSANTS DURING PREGNANCY: RESULTS OF A COHORT STUDY
OUTCOMES OF INFANTS EXPOSED TO MULTIPLE ANTIDEPRESSANTS DURING PREGNANCY: RESULTS OF A COHORT STUDY A Einarson 1, J Choi 1, G Koren 1,2, TR Einarson 1,2 1 The Motherisk Program, The Hospital for Sick Children,
More informationManagement of Epilepsy in Pregnancy
Management of Epilepsy in Pregnancy September 7, 2018 Stephanie Paolini, MD Clinical Instructor/Women s Neurology Fellow UPMC Neurology We ve come a long way Sterilization of people with epilepsy was legal
More informationIssues for Women with Epilepsy
Issues for Women with Epilepsy Tiffany N. Townsend MDCM, FRCPC Clinical Assistant Professor, Division of Neurology Co- Director, VGH Epilepsy Program Issues arise at all stages of a woman s s life Issues
More informationGestational Diabetes. Benjamin Byers, D.O., FACOG Center for Maternal and Fetal Care Bryan Physician Network
Gestational Diabetes Benjamin Byers, D.O., FACOG Center for Maternal and Fetal Care Bryan Physician Network Outline Definition Prevalence Risk factors complications Diagnosis Management Nonpharmacologic
More informationPre-Gestational Diabetes: A Public Health Growth Industry. Evan Klass, MD, FACP Associate Dean, Statewide Initiatives Director, Project ECHO-Nevada
Pre-Gestational Diabetes: A Public Health Growth Industry Evan Klass, MD, FACP Associate Dean, Statewide Initiatives Director, Project ECHO-Nevada Goals for today 1) Recognize the importance of pregestational
More informationPrescriber and Pharmacy Guide for the Opsumit REMS Program
Prescriber and Pharmacy Guide for the Opsumit REMS Program (Risk Evaluation and Mitigation Strategy) including BOXED WARNING for teratogenicity. Risk of teratogenicity Introduction to Opsumit (macitentan)
More informationMaternal Diabetes in Canada: 2004/ /15. Presented by: Dr. Chantal Nelson Canadian Perinatal Surveillance System
Maternal Diabetes in Canada: 2004/05-2014/15 Presented by: Dr. Chantal Nelson Canadian Perinatal Surveillance System Outline Introduction Methods Results Discussion 2 Introduction Both type 1 and type
More informationOral glucose lowering agents in gestational diabetes. Yes: E. Sobngwi (Cameroon) No: A. Vambergue (France)
Oral glucose lowering agents in gestational diabetes Yes: E. Sobngwi (Cameroon) No: A. Vambergue (France) CONTROVERSIES Oral glucose lowering agents in gestational diabetes «NO» Pr Anne VAMBERGUE Department
More informationMaternal and Fetal Outcomes After Lamotrigine Use in Pregnancy: A Retrospective Analysis from an Urban Maternal Mental Health Centre in New Zealand
General Psychiatry Key Words: lamotrigine, mood stabilisers, bipolar disorder, fetal and maternal outcomes Maternal and Fetal Outcomes After Lamotrigine Use in Pregnancy: A Retrospective Analysis from
More informationPrenatal Care of Women Who Give Birth to Children with Fetal Alcohol Spectrum Disorder Are we missing an opportunity for prevention?
Prenatal Care of Women Who Give Birth to Children with Fetal Alcohol Spectrum Disorder Are we missing an opportunity for prevention? Deepa Singal, PhD Candidate 1 Manitoba Centre for Health Policy Manitoba
More informationMany studies have shown obesity to be a
Eur Respir J 2010; 35: 1235 1242 DOI: 10.1183/09031936.00192408 CopyrightßERS 2010 Body mass index as predictor for asthma: a cohort study of 118,723 males and females V. Hjellvik, A. Tverdal and K. Furu
More informationDiabetes in obstetric patients
Diabetes in obstetric patients Swedish Society of Obstetric Anaesthesia & Intensive Care Anita Banerjee Obstetric Physician Diabetes & Endocrinology Consultant Outline Scope of the problem Diabetes and
More informationClinical Study Birth Weight in Type 1 Diabetic Pregnancy
Obstetrics and Gynecology International Volume 2010, Article ID 397623, 4 pages doi:10.1155/2010/397623 Clinical Study Birth Weight in Type 1 Diabetic Pregnancy Jacquemyn Yves, 1 Vandermotte Valerie, 1
More informationSupplementary Online Content
Supplementary Online Content Viktorin A, Uher R, Kolevzon A, Reichenberg A, Levine SZ, Sandin S. Association of antidepressant medication use during pregnancy with intellectual disability in offspring.
More informationEarly Intervention in Pregnancy
Early Intervention in Pregnancy Dr Lucy Mackillop Obstetric Physician Honorary Senior Clinical Lecturer Women s Centre Oxford University Hospitals NHS Foundation Trust TVSCN conference 17 th January 2017
More informationARTICLE. Neonate Characteristics After Maternal Use of Antidepressants in Late Pregnancy. 1-8 HAVE BEEN PUBlished
Neonate Characteristics After Maternal Use of Antidepressants in Late Pregnancy Bengt Källén, MD, PhD ARTICLE Background: Exposure to antidepressants during the third trimester of pregnancy has been associated
More informationEpilepsy and EEG in Clinical Practice
Mayo School of Professional Development Epilepsy and EEG in Clinical Practice November 10-12, 2016 Hard Rock Hotel at Universal Orlando Orlando, FL Course Directors Jeffrey Britton, MD and William Tatum,
More informationThe NorPen Register Project
The NorPen Register Project, Professor Karolinska Institutet Department of Medicine Solna Clinical Epidemiology Unit, T2 Karolinska University Hospital Stockholm, Sweden 20 februari 2015 1 NorPen was established
More informationExamples of Nordic collaborations: benefits and challenges
Examples of Nordic collaborations: benefits and challenges There are numerous well working ongoing Nordic research collaborations, and some Nordic organizations that have a long track record of systematic
More informationCourse and Treatment of Depression and Bipolar Illness during Pregnancy : Knowns and Unknowns
Course and Treatment of Depression and Bipolar Illness during Pregnancy : Knowns and Unknowns Lee S. Cohen, MD Director, Ammon-Pinizzotto Center for Women s Mental Health Massachusetts General Hospital
More informationDiabetes in Pregnancy
JSAFOG Diabetes in Pregnancy CONTEMPORARY REVIEW ARTICLE Diabetes in Pregnancy Neeta Deshpande Consultant, Diabetologist and Bariatric Physician, Belgaum Diabetes Center, Belgaum, Karnataka, India Correspondence:
More informationPregnancy. General Principles of Prescribing in Pregnancy (The Maudsley, 12 th Edition)
Pregnancy General Principles of Prescribing in Pregnancy (The Maudsley, 12 th Edition) In all women of child bearing potential Always discuss the possibility of pregnancy; half of all pregnancies are unplanned
More informationPerinatal Mental Health: Prescribing Guidance for Trust Prescribers and GPs
Perinatal Mental Health: Prescribing Guidance for Trust Prescribers and GPs (Version 3 January 2015) Principal Author: Dr Jenny Cooke Consultant Psychiatrist, Brighton & Hove Perinatal Mental Health Service
More informationPregestational and Gestational Diabetes
Pregestational and Gestational Diabetes Francis S. Nuthalapaty, MD Greenville Health System University of South Carolina School of Medicine - Greenville Case History 30 year old black female presents to
More informationDownloaded from jssu.ssu.ac.ir at 13:41 IRDT on Friday March 22nd p<0.05 :
51-57 1384 4 3 2 1*. :... BALB/c 81 (Clinical trial) :. 6 (30 g (30 mg/kg) (45 mg/kg) /.. Duncan LSD ANOVA...p
More informationBMJ Open. Pharmacology and therapeutics. Maternal medicine < OBSTETRICS, Depression & mood disorders < PSYCHIATRY, EPIDEMIOLOGY
Combined use of selective serotonin reuptake inhibitor and sedatives/hypnotics during pregnancy: Risk of relatively severe congenital malformations or cardiac defects. A register study Journal: Manuscript
More informationPolicies and approaches to increase access essential medicines to treat major NCDs in both public and private facilities
Policies and approaches to increase access essential medicines to treat major NCDs in both public and private facilities Prof RohiniFernandopulleMBBS (Cey),PhD, FCGP(SL) Clinical Pharmacologists Sir John
More informationCurrent Trends in Diagnosis and Management of Gestational Diabetes
Current Trends in Diagnosis and Management of Gestational Diabetes Shreela Mishra, MD Assistant Clinical Professor UCSF Fresno Medical Education Program 2/2/2019 Disclosures No disclosures 2/2/19 Objectives
More informationPreconception Care for Women with Pregestational Diabetes: Information for the Family Nurse Practitioner
Brigham Young University BYU ScholarsArchive All Student Publications 2014-07-21 Preconception Care for Women with Pregestational Diabetes: Information for the Family Nurse Practitioner Kathryn Conover
More informationAntidepressants. Professor Ian Jones May /WalesMentalHealth
Antidepressants Professor Ian Jones May 2017 www.ncmh.info @ncmh_wales /WalesMentalHealth 029 2074 4392 info@ncmh.info We identified 19 740 pregnancies exposed to an antidepressant at some point during
More informationCancer and pharmacoepidemiology in Finland. Information sources and research possibilities
Cancer and pharmacoepidemiology in Finland Information sources and research possibilities What I will talk about Register-based data sources available in Finland Register linkage method Available background
More informationMedical Screening. Dr. Catherine Watt Epidemiologist
Medical Screening Dr. Catherine Watt Epidemiologist Training Course in Sexual and Reproductive Health Research Geneva 2017 Objectives of this presentation After reading this presentation the student will:
More informationAssessing the Utility of the General Practice Research Database (GPRD) to Identify Major Congenital Heart Defects.
Assessing the Utility of the General Practice Research Database (GPRD) to Identify Major Congenital Heart Defects Keele Elise Wurst A dissertation submitted to the faculty of the University of North Carolina
More informationLow Birth Weight Increases Risk for End-Stage Renal Disease
JASN Express. Published on December 5, 2007 as doi: 10.1681/ASN.2007020252 Low Birth Weight Increases Risk for End-Stage Renal Disease Bjørn Egil Vikse,* Lorentz M. Irgens, Torbjørn Leivestad, Stein Hallan,
More informationPostnatal Care for Women with Type 1 or Type 2 Diabetes
Postnatal Care for Women with Type 1 or Type 2 Diabetes Maternity Patient Information Leaflet Introduction Congratulations! Now you have had your baby, your insulin requirements will be reduced. This is
More informationCitation for published version (APA): Boersma-Jentink, J. (2011). Risk assessment of antiepileptic drugs in pregnancy Groningen: s.n.
University of Groningen Risk assessment of antiepileptic drugs in pregnancy Boersma-Jentink, Janneke IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to
More informationGestational Diabetes. Gestational Diabetes:
Gestational Diabetes Detection and Management Steven Gabbe, MD The Ohio State University Medical Center Gestational Diabetes: Detection and Management Learning Objectives: At the conclusion of this presentation,
More informationDiabetes in Pregnancy: The Risks For Two Patients
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/the-connect-dialogues/diabetes-in-pregnancy-the-risks-for-twopatients/1793/
More informationVALPROATE. (Epilim, Depakote ) Patient Information Booklet
VALPROATE (Epilim, Depakote ) Patient Information Booklet This booklet contains key information about the risks of valproate in pregnancy. This booklet is for you, if you are a girl or a woman taking any
More informationEpilepsy in Pregnancy Guideline
RESTRICTED UNTIL APPROVED Epilepsy in Pregnancy Guideline Guideline Number: 633 Supersedes: Classification Clinical Version No: Date of EqIA: Approved by: Date Approved: Date made active: Review Date:
More informationSurveillance report Published: 8 June 2017 nice.org.uk. NICE All rights reserved.
Surveillance report 2017 Antenatal and postnatal mental health: clinical management and service guidance (2014) NICE guideline CG192 Surveillance report Published: 8 June 2017 nice.org.uk NICE 2017. All
More informationWang Linhong, Deputy Director, Professor National Center for Women and Children s Health, China CDC
Maternal and Child Health in China Wang Linhong, Deputy Director, Professor National Center for Women and Children s Health, China CDC Table of Contents 1 MCH Development and Situation in China 2 MCH Resources
More informationAssessment of knowledge and education relating to asthma during pregnancy among women of childbearing age
Al Ghobain et al. Asthma Research and Practice (2018) 4:2 DOI 10.1186/s40733-017-0038-x RESEARCH Open Access Assessment of knowledge and education relating to asthma during pregnancy among women of childbearing
More informationPregnancy and Diabetes
Pregnancy and Diabetes Aim(s) and objective(s) This guideline aims to highlight the importance of maintaining good glycaemic control in women of childbearing age contemplating pregnancy, during pregnancy
More informationFACT SHEET 1. Breastfeeding in Ontario Notable Trends within the Province
Breastfeeding in Ontario Notable Trends within the Province In order to gain a greater understanding of breastfeeding in Ontario, breastfeeding data was retrieved from the Better Outcomes Registry and
More informationTherapy Insight: clinical management of pregnant women with epilepsy
Therapy Insight: clinical management of pregnant women with epilepsy Alison M Pack SUMMARY In pregnant women with epilepsy who are being treated with antiepileptic drugs (AEDs), careful clinical management
More information